A phase I trial (NCT02777710) combining durvalumab (PD-L1 inhibitor) and pexidartinib (CSF1R inhibitor) in advanced CRC/pancreatic cancer showed 21% achieving stable disease ≥2 months (130). This evidence concerns the gene CSF1R and colorectal carcinoma.